Monograph Details
|
|
Ob/Gyn
> Menopause and HRT
|
|
CENESTIN |
| Manufacturer |
|
Duramed Pharmaceuticals, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Estrogen. |
| Generic Name |
|
Synthetic conjugated estrogens, A 0.3mg, 0.45mg, 0.625mg, 0.9mg, 1.25mg; tabs. |
| Indications |
|
Moderate to severe vasomotor menopausal symptoms. Vulvar and vaginal atrophy. |
| Children |
|
Not applicable. |
| Adults |
|
Give cyclically (3 weeks on, 1 week off). Menopause symptoms: initially 0.625mg/day, may titrate to 1.25mg/day. Atrophic vaginitis: 0.3mg/day. Reevaluate periodically. |
| Contraindications |
|
Breast or estrogen-dependent carcinoma (unless palliative). Undiagnosed abnormal vaginal bleeding. Thromboembolic disorders. Thrombophlebitis. Liver dysfunction or disease. Pregnancy (Cat.X). |
| Precautions |
|
Increased risk of endometrial carcinoma or hyperplasia in women with an intact uterus (consider adding progestin). Renal dysfunction. Gallbladder disease. Familial hyperlipoproteinemia. Conditions aggravated by fluid retention. Bone disease associated with hypercalcemia. Depression. Do initial complete physical and repeat every 6–12 months (include BP, mammogram, PAP smear). Discontinue if jaundice occurs and during immobilization or 2 weeks before surgery associated with thromboembolism. Nursing mothers: not recommended. |
| Adverse Reactions |
|
Nausea, vomiting, abdominal pain, irregular bleeding, headache, insomnia, edema, weight changes, hypertonia, leg cramps, hypertension, mastodynia, chloasma. Long-term continuous use may increase risk of estrogen-dependent cancers, others. Increased risk of gallbladder disease, thromboembolic disorders. |
| How Supplied |
|
Tabs—30, 100, 1000 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
